The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Open accessAbstract
Rituximab is a chimeric mouse/human monoclonal antibody (mAb) therapy with binding specificity to CD20. It was the first therapeutic antibody approved for oncology patients and was the top-selling oncology drug for nearly a decade with sales reaching $8.58 billion in 2016. Since its initial approval in 1997, it has improved outcomes in all B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia. Despite widespread use, most mechanistic data have been gathered from in vitro studies while the roles of the various response mechanisms in humans are still largely undetermined. Polymorphisms in Fc gamma receptor and complement protein genes have been implicated as potential predictors of differential response to rituximab, but have not yet shown sufficient influence to impact clinical decisions. Unlike most targeted therapies developed today, no known biomarkers to indicate target engagement/tumor response have been identified, aside from reduced tumor burden. The lack of companion biomarkers beyond CD20 itself has made it difficult to predict which patients will respond to any given anti-CD20 antibody. In the past decade, two new anti-CD20 antibodies have been approved: ofatumumab, which binds a distinct epitope of CD20, and obinutuzumab, a mAb derived from rituximab with modifications to the Fc portion and to its glycosylation. Both are fully humanized and have biological activity that is distinct from that of rituximab. In addition to these new anti-CD20 antibodies, another imminent change in targeted lymphoma treatment is the multitude of biosimilars that are becoming available as rituximab’s patent expires. While the widespread use of rituximab itself will likely continue, its biosimilars will increase global access to the therapy. This review discusses current research into mechanisms and potential biomarkers of rituximab response, as well as its biosimilars and the newer CD20 binding mAb therapies. Increased ability to assess the effectiveness of rituximab in an individual patient, along with the availability of alternative anti-CD20 antibodies will likely lead to dramatic changes in how we use CD20 antibodies going forward.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Pfreundschuh, M., Trümper, L., Österborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.-L., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70664-7 · Cited by 2,076
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Rovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,039
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Pfreundschuh, M., Kuhnt, E., Trümper, L., Österborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70235-2 · Cited by 792
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Maloney, D. G., Grillo-López, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 636
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., & Keating, M. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2165 · Cited by 586
Natural killer cell memory in infection, inflammation and cancer
Cerwenka, A., & Lanier, L. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.9 · Cited by 576
Production of functional chimaeric mouse/human antibody
Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 550
Arnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Vose, J. M., Link, B. K., Grossbard, M. L., Czuczman, M., Grillo-Lopez, A., Gilman, P., Lowe, A., Kunkel, L. A., & Fisher, R. I. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.389 · Cited by 417
Vitolo, U., Trněný, M., Belada, D., Burke, J. M., Carella, A. M., Chua, N., Abrisqueta, P., Demeter, J., Flinn, I., Hong, X., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3402 · Cited by 417
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., Ribrag, V., Feugier, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701769 · Cited by 416
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
Ardeshna, K. M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C. F. E., Miall, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70027-0 · Cited by 395
Xu-Monette, Z. Y., Wu, L., Visco, C., Tai, Y. C., Tzankov, A., Liu, W.-M., Montes-Moreno, S., Dybkær, K., Chiu, A., Orazi, A., et al. (2012) · Blood · doi:10.1182/blood-2012-05-433334 · Cited by 388
Self-citationCombining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 375
Drugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
Schulz, H., Bohlius, J. F., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Herold, M., Dreyling, M., Hallek, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362
B-cell anergy: from transgenic models to naturally occurring anergic B cells?
Cambier, J. C., Gauld, S. B., Merrell, K. T., & Vilen, B. J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2133 · Cited by 348
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K. D., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334
Neri, S., Mariani, E., Meneghetti, A., Cattini, L., & Facchini, A. (2001) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.6.1131-1135.2001 · Cited by 306
Diffuse large B-cell lymphoma: R-CHOP failure—what to do?
Coiffier, B., & Sarkozy, C. (2016) · Hematology · doi:10.1182/asheducation-2016.1.366 · Cited by 292
Hoelzer, D., Walewski, J., Döhner, H., Viardot, A., Hiddemann, W., Spiekermann, K., Serve, H., Dührsen, U., Hüttmann, A., Thiel, E., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563627 · Cited by 289
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Grever, M. R., Abdel-Wahab, O., Andritsos, L. A., Banerji, V., Barrientos, J., Blachly, J. S., Call, T. G., Catovsky, D., Dearden, C., Demeter, J., et al. (2017) · Blood · doi:10.1182/blood-2016-01-689422 · Cited by 289
How I treat Waldenström macroglobulinemia
Treon, S. P. (2015) · Blood · doi:10.1182/blood-2015-01-553974 · Cited by 287
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Hallek, M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24826 · Cited by 282
Mellstedt, H., Niederwieser, D., & Ludwig, H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm345 · Cited by 271
Treatment of Waldenström’s Macroglobulinemia With Rituximab
Dimopoulos, M. A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N. A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.039 · Cited by 253
Mechanisms of action of CD20 antibodies.
Boross, P., & Leusen, J. H. W. (2012) · PubMed · Cited by 252
Sartore-Bianchi, A., Ardini, E., Bosotti, R., Amatu, A., Valtorta, E., Somaschini, A., Raddrizzani, L., Palmeri, L., Banfi, P., Bonazzina, E., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv306 · Cited by 245
Mouse CD20 expression and function
Uchida, J. (2004) · International Immunology · doi:10.1093/intimm/dxh009 · Cited by 244
Czuczman, M. S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J., & Hernandez-Ilizaliturri, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1254 · Cited by 232
Therapeutic antibodies: past, present and future
Leavy, O. (2010) · Nature Reviews Immunology · doi:10.1038/nri2763 · Cited by 215
Perforin: an important player in immune response
Osińska, I., Popko, K., & Demkow, U. (2014) · Central European Journal of Immunology · doi:10.5114/ceji.2014.42135 · Cited by 214
Weng, W.-K., Czerwinski, D., Timmerman, J., Hsu, F. J., & Levy, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.003 · Cited by 191
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
Iorio, R., Damato, V., Alboini, P. E., & Evoli, A. (2015) · Journal of Neurology · doi:10.1007/s00415-014-7532-3 · Cited by 188
Ribrag, V., Koscielny, S., Bosq, J., Leguay, T., Casasnovas, O., Fornecker, L.-M., Recher, C., Ghesquieres, H., Morschhauser, F., Girault, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01317-3 · Cited by 185
B lymphocytes in neuromyelitis optica
Bennett, J. L., O'Connor, K. C., Bar-Or, A., Zamvil, S. S., Hemmer, B., Tedder, T. F., von Büdingen, H.-C., Stuve, O., Yeaman, M. R., Smith, T. J., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000104 · Cited by 182
Biosimilars: Key regulatory considerations and similarity assessment tools
Kirchhoff, C. F., Wang, X. M., Conlon, H. D., Anderson, S., Ryan, A. M., & Bose, A. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26438 · Cited by 179
Herndler-Brandstetter, D., Shan, L., Yao, Y., Stecher, C., Plajer, V., Lietzenmayer, M., Strowig, T., de Zoete, M. R., Palm, N. W., Chen, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705301114 · Cited by 179
Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, C. H. T., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177
Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different Regimens
Wang, H., Liu, C., Li, Y., & Huang, Y. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-2116 · Cited by 175
Store-operated Cation Entry Mediated by CD20 in Membrane Rafts
Li, H., Ayer, L. M., Lytton, J., & Deans, J. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308802200 · Cited by 172
Primary mediastinal large B-cell lymphoma
Martelli, M., Ferreri, A., Di Rocco, A., Ansuinelli, M., & Johnson, P. W. M. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.009 · Cited by 163
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Johnson, N. A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L. H., Chhanabhai, M., Brinkman, R. R., Connors, J. M., Weng, A. P., et al. (2009) · Blood · doi:10.1182/blood-2008-09-177469 · Cited by 163
BCL2 mutations in diffuse large B-cell lymphoma
Schuetz, J. M., Johnson, N. A., Morin, R. D., Scott, D. W., Tan, K. X., Neriah, S. B., Boyle, M., Slack, G. W., Marra, M. A., Connors, J. M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.378 · Cited by 161
Wierda, W. G., Padmanabhan, S., Chan, G. W., Gupta, I. V., Lisby, S., Österborg, A., & for the Hx-CD20-406 Study Investigators (2011) · Blood · doi:10.1182/blood-2011-04-348656 · Cited by 160
Cartron, G., de Guibert, S., Dilhuydy, M., Morschhauser, F., Leblond, V., Dupuis, J., Mahé, B., Bouabdallah, R., Lei, G., Wenger, M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586610 · Cited by 157
Beum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J. M., Engelberts, P. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101189 · Cited by 140
Novel CD20 monoclonal antibodies for lymphoma therapy
Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-64 · Cited by 140
Golay, J., & Introna, M. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.02.011 · Cited by 135
Analytical characterization of biosimilar antibodies and Fc-fusion proteins
Beck, A., Diemer, H., Ayoub, D., Debaene, F., Wagner‐Rousset, E., Carapito, C., DORSSELAER, A. V., & Cianférani, S. (2013) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2013.02.014 · Cited by 134
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
Du, J., Wang, H., Zhong, C., Peng, B., Zhang, M., Li, B., Huo, S., Guo, Y., & Ding, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701654200 · Cited by 134
The future of anti-CD20 monoclonal antibodies: are we making progress?
Alduaij, W., & Illidge, T. (2011) · Blood · doi:10.1182/blood-2010-07-298356 · Cited by 131
Valgardsdottir, R., Cattaneo, I., Klein, C., Introna, M., Figliuzzi, M., & Golay, J. (2017) · Blood · doi:10.1182/blood-2016-08-735605 · Cited by 124
Reichert, J. M., & Pavlou, A. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1386 · Cited by 122
Dörner, T., Kinnman, N., & Tak, P. P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.001 · Cited by 122
(2013) · doi:10.7717/peerj.36 · Cited by 115
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114
Jazirehi, A. R., Gan, X.-H., de Vos, S., Emmanouilides, C. E., & Bonavida, B. (2003) · PubMed · Cited by 111
Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 105
TP53 mutation and survival in aggressive B cell lymphoma
Zenz, T., Kreuz, M., Fuge, M., Klapper, W., Horn, H., Staiger, A. M., Winter, D., Helfrich, H., Hüellein, J., Hansmann, M., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30838 · Cited by 103
Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Velmurugan, R., Challa, D. K., Ram, S., Ober, R. J., & Ward, E. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0335 · Cited by 100
Seyfizadeh, N., Seyfizadeh, N., Hasenkamp, J., & Huerta‐Yépez, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.001 · Cited by 99
Awasthi, A., Ayello, J. S., van de Ven, C., Elmacken, M., Sabulski, A., Barth, M. J., Czuczman, M. S., Islam, H. K., Klein, C., & Cairo, M. S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13764 · Cited by 98
Current perspective on rituximab in rheumatic diseases
Schioppo, T., & Ingegnoli, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s139248 · Cited by 98
Rafiq, S., Butchar, J. P., Cheney, C. M., Mo, X. M., Trotta, R., Caligiuri, M. A., Jarjoura, D. G., Tridandapani, S., Muthusamy, N., & Byrd, J. C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202588 · Cited by 95
Fischer, L., Penack, O., Gentilini, C., Nogai, A., Muessig, A., Thiel, E., & Uharek, L. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.015 · Cited by 87
Salles, G., Seymour, J. F., Feugier, P., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.509.509 · Cited by 83
Hayes, J. M., Frostell, Å., Karlsson, R., Müller, S., Millán‐Martín, S., Pauers, M., Reuss, F., Cosgrave, E. F. J., Annerén, C., Davey, G. P., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.066944 · Cited by 83
Martin, P., Jung, S., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Shea, T., Hsi, E. D., Ruan, J., Smith, S. E., Leonard, J. P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx496 · Cited by 83
Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL
Middleton, O., Cosimo, E., Dobbin, E., McCaig, A. M., Clarke, C., Brant, A., Leach, M., Michie, A. M., & Wheadon, H. (2014) · Leukemia · doi:10.1038/leu.2014.146 · Cited by 82
Clinical trial development for biosimilars
Alten, R., & Cronstein, B. N. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.04.002 · Cited by 77
Kim, W. S., Buske, C., Ogura, M., Jurczak, W. J., Sancho, J., Zhavrid, E. A., Kim, J. S., Hernández‐Rivas, J., Prokharau, A., Vasilică, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30120-5 · Cited by 77
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Nowakowski, G. S., Blum, K. A., Kahl, B. S., Friedberg, J. W., Baizer, L., Little, R. F., Maloney, D. G., Sehn, L. H., Williams, M. E., Wilson, W. H., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw257 · Cited by 75
Optimizing therapy for nodal marginal zone lymphoma
Thiéblemont, C., Molina, T. J., & Davi, F. (2016) · Blood · doi:10.1182/blood-2015-12-624296 · Cited by 74
Whither Radioimmunotherapy: To Be or Not To Be?
Green, D. J., & Press, O. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2523 · Cited by 67
Davies, A. J., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P. J., Rule, S. A., Rummel, M., McIntyre, C., Smith, R. B. W., & Badoux, X. C. A. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0610-z · Cited by 67
Efficacy of rituximab in refractory neuromyelitis optica
Collongues, N., Brassat, D., Maillart, É., Labauge, P. M., Ouallet, J., Dalliere, C. C., Moreau, T., Bourre, B., Papeix, C., Brochet, B., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515602337 · Cited by 66
Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., Fanning, S. R., Klein, L. M., Greenwald, D. R., Sportelli, P., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14447 · Cited by 64
Arana, P., Paiva, B., Puig, N., Cedena, M., Cordón, L., Vídriales, M., Martínez‐López, J., Ocio, E. M., Hernández, M., Teruel, A. I., et al. (2015) · Blood · doi:10.1182/blood.v126.23.721.721 · Cited by 64
Yamashita, M., Kitano, S., Aikawa, H., Kuchiba, A., Hayashi, M., Yamamoto, N., Tamura, K., & Hamada, A. (2016) · Scientific Reports · doi:10.1038/srep19772 · Cited by 63
Vidal, L., Gafter‐Gvili, A., Salles, G. A., Bousseta, S., Oberman, B., Rubin, C., van Oers, M. H. J., Fortpied, C., Ghielmini, M. E. G., Pettengell, R., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.021 · Cited by 63
Bezombes, C., Fournié, J., & Laurent, G. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0154 · Cited by 58
Rituximab: 13 open questions after 20years of clinical use
Pavanello, F., Zucca, E., & Ghielmini, M. E. G. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.015 · Cited by 58
Perz, J. B., Topaly, J., Früehauf, S., Hensel, M., & Ho, A. D. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190210178 · Cited by 57
Unruh, T. L., Li, H., Mutch, C. M., Shariat, N., Grigoriou, L., Sanyal, R., Brown, C. B., & Deans, J. P. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02213.x · Cited by 56
Optimization of rituximab for the treatment of DLBCL : increasing the dose for elderly male patients
Pfreundschuh, M. G., Murawski, N., Zeynalova, S., Ziepert, M., Loeffler, M., Hänel, M., Dierlamm, J., Keller, U. B., Dreyling, M. H., Trümper, L. H. P., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14860 · Cited by 56
The regulatory framework of biosimilars in the European Union
Minghetti, P., Rocco, P., Cilurzo, F., Vecchio, L. D., & Locatelli, F. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.001 · Cited by 55
Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
Dillman, R. O. (2006) · Clinical and Experimental Medicine · doi:10.1007/s10238-006-0087-6 · Cited by 51
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives
Chiappella, A., Castellino, A., Nicolosi, M., Santambrogio, E., & Vitolo, U. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1305264 · Cited by 49
Rituximab in Chronic Lymphocytic Leukemia
Jaglowski, S. M., & Byrd, J. C. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.005 · Cited by 48
Comparability study of Rituximab originator and follow-on biopharmaceutical
Montacir, O., Montacir, H., Eravci, M., Springer, A., Hinderlich, S., Saadati, A., & Parr, M. K. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.03.029 · Cited by 47
Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies
Khan, M., Siddiqi, R. L., & Thompson, P. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3149-9 · Cited by 44
Singh, V. K., Gupta, D., & Almasan, A. (2015) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000373 · Cited by 43
Chen, D. R., & Cohen, P. L. (2012) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.7 · Cited by 42
Current prognostic and predictive factors in follicular lymphoma
Sorigué, M., & Sancho, J. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3154-z · Cited by 38
Paludo, J., Abeykoon, J. P., Kumar, S. K., Shreders, A. J., Ailawadhi, S., Gertz, M. A., Kourelis, T., King, R. L., Reeder, C. B., Leung, N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14826 · Cited by 36
Czuczman, M. S., Kahanic, S. P., Forero, A., Davis, G., Munteanu, M. C., Neste, É. V. D., Offner, F. C., Bron, D., Quick, D. P., & Fowler, N. H. (2015) · Annals of Hematology · doi:10.1007/s00277-014-2269-8 · Cited by 35
Hicks, S. W., Lai, K. C., Gavrilescu, L. C., Yi, Y., Sikka, S., Shah, P., Kelly, M. E., Lee, J., Lanieri, L., Ponte, J. F., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.06.001 · Cited by 34
Treatment of splenic marginal zone lymphoma
Kalpadakis, C. H., Pangalis, G. A., Angelopoulou, M. K., & Vassilakopoulos, T. P. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.07.004 · Cited by 31
Mishima, Y., Terui, Y., Mishima, Y. M., Kuniyoshi, R., Matsusaka, S., Mikuniya, M., Kojima, K., & Hatake, K. (2012) · International Immunology · doi:10.1093/intimm/dxs048 · Cited by 30
Small, G. W., McLeod, H. L., & Richards, K. L. (2013) · PeerJ · doi:10.7717/peerj.31 · Cited by 29
Self-citationAssessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity
Miranda‐Hernández, M. P., López‐Morales, C. A., Ramírez-Ibáñez, N. D., Piña-Lara, N., Pérez, N. O., Molina-Pérez, A., Revilla-Beltri, J., Flores-Ortiz, L. F., & Medina‐Rivero, E. (2015) · Journal of Immunology Research · doi:10.1155/2015/910763 · Cited by 29
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations
Dreyling, M. H., Aurer, I., Cortelazzo, S., Hermine, O., Heß, G., Jerkeman, M., Gouill, S. L., Ribrag, V., Trněný, M., Visco, C., et al. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1403602 · Cited by 29
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Preprint
Amin, A. D., Peters, T. L., Li, L., Rajan, S. S., Choudhari, R., Puvvada, S. D., & Schatz, J. H. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001719 · Cited by 27
Danese, M. D., Reyes, C. M., Gleeson, M. L., Halperin, M., Skettino, S. L., & Mikhael, J. R. (2016) · Medical Care · doi:10.1097/mlr.0000000000000486 · Cited by 24
Rogers, L. M., Mott, S. L., Smith, B. J., Link, B. K., Sahin, D. G., & Weiner, G. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1275 · Cited by 23
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
Al‐Sawaf, O., Fischer, K., Engelke, A., Pflug, N., Hallek, M. J., & Goede, V. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s104869 · Cited by 23
Magnes, T., Melchardt, T., Hufnagl, C., Weiss, L., Mittermair, C., Neureiter, D., Klieser, E., Rinnerthaler, G., Roesch, S., Gaggl, A., et al. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.37 · Cited by 23
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
Castellino, A., & Vitolo, U. (2016) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.009 · Cited by 21
Ofatumumab in the treatment of non-Hodgkin’s lymphomas
Karlin, L., & Coiffier, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1055241 · Cited by 20
Burkhardt, B., Yavuz, D., Zimmermann, M., Schieferstein, J., Kabíčková, E., Attarbaschi, A., Lisfeld, J., Reiter, A., Makarova, O., Worch, J., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2731-x · Cited by 20
Butler, L. A., Tam, C. S. L., & Seymour, J. F. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.05.002 · Cited by 20
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-017-3147-y · Cited by 20
Rethinking the INN system for therapeutic antibodies
Pottier, J., Chastang, R., Dumet, C., & Watier, H. (2016) · mAbs · doi:10.1080/19420862.2016.1255520 · Cited by 18
Advances in chronic lymphocytic leukemia pharmacotherapy
Gomes, L. C., Ferrão, A. L. M., Evangelista, F. C. G., de Almeida, T. D., Barbosa, R. C., Ferriani, M. D. G. C., & Sabino, A. D. P. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.105 · Cited by 18
Update on therapeutic options in Waldenström macroglobulinemia
Leleu, X. P., Gay, J., Roccaro, A. M., Moreau, A., Poulain, S., Duléry, R., Champs, B. B. D., Robu, D., & Ghobrial, I. M. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01171.x · Cited by 17
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Rocco, A. D., Angelis, F. D., Ansuinelli, M., Foà, R., & Martelli, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1356714 · Cited by 16
Yin, H., Meng, T., Shu, L., Mao, M., Zhou, L., Chen, H., & Song, D. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13010 · Cited by 14
Modeling Natural Killer Cell Targeted Immunotherapies
Lopez‐Lastra, S., & Santo, J. P. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00370 · Cited by 13
Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
Dhillon, S. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0485-6 · Cited by 9
Current options to manage Waldenström’s macroglobulinemia
Benevolo, G., Nicolosi, M., Santambrogio, E., & Vitolo, U. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1339596 · Cited by 6
Cited by
mRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385
Ångström-resolution fluorescence microscopy
Reinhardt, S. C. M., Masullo, L. A., Baudrexel, I., Steen, P. R., Kowalewski, R., Eklund, A. S., Strauss, S., Unterauer, E. M., Schlichthaerle, T., Strauss, M. T., et al. (2023) · Nature · doi:10.1038/s41586-023-05925-9 · Cited by 298
Ebata, S., Yoshizaki, A., Oba, K., Kashiwabara, K., Ueda, K., Uemura, Y., Watadani, T., Fukasawa, T., Miura, S., Yoshizaki-Ogawa, A., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00107-7 · Cited by 274
The role of complement in the mechanism of action of therapeutic anti-cancer mAbs
Golay, J., & Taylor, R. P. (2020) · Antibodies · doi:10.3390/antib9040058 · Cited by 104
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Metadata
- Authors
- Pierpont, T. M., Limper, C. B., & Richards, K. L.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-04
- Volume
- 8
- Pages
- 163-163
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2806838331
- Cited by
- 374
- References
- 141
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.